EI
FATE icon

Ellevest Inc’s Fate Therapeutics FATE Stock Holding History

Ellevest Inc’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21
Closed -$1K – 1679
2022
Q2 		$1K Sell
21
-46
-69% -$1.27K ﹤0.01% 1248
2022
Q1 		$3K Buy
+67
New +$2.59K ﹤0.01% 1126
2021
Q4 		– Sell
-26
Closed -$2K – 1486
2021
Q3 		$2K Buy
+26
New +$2.04K ﹤0.01% 1131

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ellevest Inc's FATE Position: Q3 2022 in Review

Ellevest Inc sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 21 shares — an estimated $1K sold.

Ellevest Inc first reported a position in FATE in Q3 2021 and held it in 3 quarters. The position peaked at $3K in Q1 2022. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Ellevest Inc reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ellevest Inc sold 21 Fate Therapeutics shares in Q3 2022, an estimated $1K.
  • Ellevest Inc first reported a position in Fate Therapeutics in Q3 2021 and held it in 3 quarters.
  • Ellevest Inc's Fate Therapeutics position peaked at $3K in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.